t2cure’s cell therapy is available through cooperating clinical centres
    t2cure cooperates with experienced partners in research and in the industry.
    t2cure's pipeline is built on clinical studies in cardiac and peripheral vascular indications
    t2cure is dedicated to the development of novel progenitor cell-based regenerative therapeutics.


    Our product t2c001 has been successfully tested in several clinical trials on improvement of cardiac function. Currently there are additional clinical studies ongoing for the treatment of acute and chronic heart diseases. One clinical study in the treatment of peripheral artery disease has been completed, and a follow up study in thromboangiitis obliterans is planned.

    In March 2008, a life report was broadcasted on German TV about t2cure’s lead product and t2cure’s collaboration with the university clinics and the blood donor service in Frankfurt. To view the movie, klick here.